

1 Incidence, risk factors, and clinical outcomes of mannitol-induced acute kidney injury among
2 acute stroke patients admitted to East Avenue Medical Center

3

4 Ralph Jefferson T. Ramos^{1¶*}, Karen S. Cabigas^{1¶}, Elyzel C. Rabara^{1¶}, Marissa Elizabeth Lim^{1¶}

5

6 ¹Section of Nephrology, Department of Internal Medicine, East Avenue Medical Center

7

8 ***Corresponding author**

9 Email: jramos1987@yahoo.com

10

11 [¶]These authors contributed equally to this work.

12

13 **Acknowledgments**

14 We thank our mentors and the staff of the Section of Nephrology in the Department of Internal
15 Medicine of the East Avenue Medical Center for their unwavering support.

16

17 **Sources of funding**

18 This study was self-funded by the authors.

19

20 **Abstract**

21 Background: In the Philippines, stroke is the second most common cause of mortality and is among
22 the five leading causes of disability. Mannitol, a hyperosmolar agent, is a mainstay for the
23 treatment of brain edema caused by elevated intracranial pressure in acute stroke patients. It is a

24 potent diuretic that may trigger intravascular volume depletion, electrolyte imbalance, and renal
25 tubular damage, which may lead to acute kidney injury in acute stroke.

26 Objective: This study aims to describe the incidence, identify the risk factors, and determine the
27 clinical outcomes of mannitol-induced acute kidney injury among acute stroke patients admitted
28 to East Avenue Medical Center from January 1, 2019, to December 31, 2021.

29 Methods: This is a retrospective study conducted at the East Avenue Medical Center, a tertiary
30 training hospital in Quezon City, Philippines. A three-year chart review of acute stroke patients
31 who developed mannitol-induced acute kidney injury (MI-AKI) was conducted.

32 Result: A total of 348 eligible acute stroke patients were included in the study. Of these, 60 patients
33 (17%) developed MI-AKI during confinement. There was a higher predominance among males
34 than females with more than half of patients (65%) belonging to the 40 to 59 years age group. The
35 risk factors identified were high National Institutes of Health Stroke Scale (NIHSS) score, chronic
36 kidney disease, possibly cardiovascular disease, such as heart failure, intraparenchymal type
37 hemorrhagic stroke, and high mannitol infusion dose $>0.40\text{g/kg}$ in more than 48 hours. A high
38 mortality rate was observed among MI-AKI patients in the study as compared with those without
39 AKI (61.67% vs 27.43%, $P<0.001$) whereas spontaneous resolution of AKI was seen in 25 patients
40 (41.67%, $P<0.001$). Only 4 patients (6.67%, $P=0.001$) who had renal replacement therapy had
41 worsening renal function compared to the 27 patients (45%, $P<0.001$) who did not receive renal
42 replacement therapy.

43 Conclusion: Risk factors for MI-AKI include moderate to severe NIHSS score, chronic kidney
44 disease 3 and above, cardiovascular disease, and high-dose mannitol infusion. Early nephrology
45 referral among patients with mannitol infusion for stroke is a must among patients who have co-
46 morbidities including chronic kidney disease stage 3 and above, and cardiovascular disease such

47 as heart failure. Serial monitoring of renal function should be performed especially for those
48 patients with moderate to severe NIHSS scores and high-dose mannitol infusion for appropriate
49 dosing to prevent MI-AKI.

50

51 **Introduction**

52 Stroke remains the Philippines' second greatest cause of mortality and was among the top
53 five causes of disability from 2009 to 2019. Stroke prevalence estimates range from 0.9% (2005)
54 to 2.6% (2017) of the general population. While seven out of ten strokes are classified as ischemic,
55 the remaining three are classified as hemorrhagic (1). Among Filipino stroke patients undergoing
56 thrombolysis, in-hospital mortality has been reported to be 14.6%, and in those who have been
57 discharged, death occurred in 3.7% (2). As a result of variability in data collection and inadequate
58 epidemiological studies, there is currently limited data on the etiological factors that lead to death
59 among Filipino stroke patients.

60 In a study conducted by Shin-Yi Lin et al 2015, a major cause of long-term morbidity and
61 mortality among acute stroke patients is the development of cerebral edema. Mannitol, a
62 hyperosmolar diuretic, has been established as a treatment for acute cerebral edema (3). It is a
63 potent diuretic that decreases elevated intracranial pressure in patients with brain edema by
64 promoting the osmotic flow of water out of the cerebral parenchyma and by autoregulatory
65 vasoconstriction. It also augments cerebral blood flow (4). Although beneficial in many cases,
66 mannitol is known to alter intravascular volume status, serum osmolality, electrolytes, creatinine,
67 and blood urea nitrogen and increase the risk of acute kidney injury (AKI) (4). Especially in high
68 doses (>0.20 kg/day or cumulative dose of >0.40 kg in 48 hours), mannitol has been found to cause
69 acute tubular necrosis when serum osmolality is above 320 Osm (4).

70 Mannitol-induced AKI (MI-AKI), also known as mannitol-induced osmotic nephrosis, is
71 characterized by structural changes that occur at a cellular level in the kidney, primarily at the
72 proximal tubule. The alterations include intracytoplasmic vacuolization and distension of tubular
73 cells (5). The form of acute renal failure in MI-AKI is often observed to be oliguric/anuric and
74 may be asymptomatic or may mimic other nephrotic conditions (5). The risk factors that have
75 been associated with MI-AKI in stroke patients include diabetes mellitus, underlying renal
76 impairment, high initial NIHSS scores, and concurrent use of diuretics (3). In patients with
77 intracranial hemorrhage, MI-AKI occurred more frequently in those who received mannitol
78 infusion at a rate of ≥ 1.34 g/kg/day compared with patients who received slower rates. In this
79 subset of patients, the independent risk factors for MI-AKI were infusion at a rate of
80 ≥ 1.34 g/kg/day, diastolic blood pressure (DBP) ≥ 100 mmHg, and glomerular filtration rate (GFR)
81 < 60 ml/min/1.73m² (6).

82 No local data has been published establishing the burden, causes, and optimal management
83 of MI-AKI among Filipino stroke patients. This study aims to describe the incidence, enumerate
84 the risk factors, and establish the clinical outcome of MI-AKI among acute stroke patients admitted
85 to East Avenue Medical Center (EAMC) from January 1, 2019, to December 31, 2021. Outlining
86 these risk factors may aid in predicting the occurrence of MI-AKI injury among adult acute stroke
87 patients and allow clinicians to create an appropriate plan of management among patients who
88 have the highest risk. Secondly, we aimed to describe the population of acute stroke patients
89 with MI-AKI in terms of:

- 90 • Demographics: age, gender, co-morbidities, medications, and estimated glomerular
91 filtration rate (eGFR) of acute stroke patients who are likely to develop mannitol-induced
92 AKI

- 93 • Identify the risk factors for MI-AKI among acute stroke patients treated with mannitol
- 94 • Dosage, cumulative dose, and duration of mannitol use among acute stroke patients who
- 95 developed MI-AKI
- 96 • Clinical outcomes such as the resolution of MI-AKI, death, or acute kidney injury requiring
- 97 renal replacement therapy upon discharge among acute stroke patients with MI-AKI
- 98 admitted to the EAMC Stroke Unit

99

100 **Materials and methods**

101 **Study design**

102 This is a three-year retrospective analysis of hospital medical records dated January 1, 2019,
103 to December 31, at the Section of Nephrology in EAMC 2021. Individual information of the
104 patients was anonymized using code numbers.

105 **Sampling and sample size**

106 Patients who were 19 years old and above, had either an acute ischemic or hemorrhagic stroke,
107 and developed AKI following mannitol administration beyond the first 48 hours of confinement
108 comprise the study group. Baseline NIHSS scores upon admission and systolic blood pressures
109 were obtained. Patients who were under renal replacement therapy (RRT), had nosocomial
110 infections, had brain tumors, and expired within 48 hours of admission were excluded. After, using
111 G*Power 3.1.9.2, a minimum of 63 patients are required for this study based on a 3.62 odds ratio
112 of diabetic patients who develop MI-AKI (3), with a 5% level of significance and 95% power.

113 **Data gathering**

114 The data extracted included the hospital codes assigned to the patients with their
115 corresponding age, sex, comorbidities, initial NIHSS scores, medications, GFR as defined by the
116 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) criteria, and mannitol
117 treatment upon admission. A list of medications such as anti-hypertensive medications,
118 nephrotoxic agents, and diuretics was listed. Lastly, the cumulative dose and the duration of
119 mannitol therapy were documented. Clinical outcomes such as the resolution of MI-AKI,
120 unimprovement either with the disposition of AKI-requiring RRT or AKI-not requiring RRT, and
121 death were likewise recorded.

122

123 **Figure 1. Patient selection process**

124 **Data processing and statistical analysis**

125 The collected data were tabulated, encoded, and analyzed using the Stata 13.1 program.
126 Descriptive statistics were used to summarize the demographic and clinical characteristics of the
127 patients. Frequency and proportion were used for categorical variables and mean and standard
128 deviation (SD) for normally distributed continuous variables. Independent sample T-test and
129 Fisher's exact/Chi-square test were used to determine the difference in mean and frequency,
130 respectively, between patients with and without MI-AKI. The odds ratio and corresponding 95%
131 confidence intervals from binary logistic regression were computed to determine significant
132 predictors for Mannitol-Induced Acute Kidney Injury. All statistical tests were two-tailed tests.
133 Shapiro-Wilk test was used to test the normality of the continuous variables. Missing values were
134 neither replaced nor estimated. Null hypotheses were rejected at a 0.05 level of significance.

135 **Results**

136 A total of 1,697 patients diagnosed with acute stroke were reviewed, of which 348 (20.5%)
 137 patients received mannitol therapy during admission. Most patients had intraparenchymal lesions,
 138 91.09%, followed by subarachnoid hemorrhage, 8.9%, and malignant infarct, 1.44% (Table 1).
 139 From the total population, 17% of patients developed MI-AKI (95% confidence interval [CI],
 140 13.42–21.63). MI-AKI occurred after the first 48 hours but not more than 7 days upon
 141 administration of mannitol for most patients.

142 **Table 1. Characteristics of stroke patients who were prescribed mannitol**

	Mannitol-Induced Acute Kidney Injury			P-value
	Total (n=348)	With (n=60, 17%)	Without (n=288, 83%)	
	Frequency (%) ± SD			
Age	52.11 ± 11.62	52.42 ± 12.51	52.05 ± 11.44	0.825
19 to 39	37 (10.63)	9 (15)	28 (9.72)	0.351
40 to 59	223 (64.08)	39 (65)	184 (63.89)	
≥60	88 (25.29)	12 (20)	76 (26.39)	
Sex				0.357
Male	242 (69.54)	45 (75)	197 (68.4)	
Female	106 (30.46)	15 (25)	91 (31.6)	
Type of stroke				0.207
Ischemic	5 (1.44)	2 (3.33)	3 (1.04)	
Hemorrhagic	343 (98.56)	58 (96.67)	285 (98.96)	
Type of hemorrhagic stroke				0.042
Subarachnoid				

Intraparenchymal	31 (8.91)	10 (16.67)	21 (7.29)	
	317 (91.09)	50 (83.33)	267 (92.71)	
NIHHS score				<0.001
Minor (1 to 4)	15 (4.31)	3 (5)	12 (4.17)	
Moderate (5 to 15)	160 (45.98)	13 (21.67)	147 (51.04)	
Moderate to severe (16 to 20)	100 (28.74)	30 (50)	70 (24.31)	
Severe (21 to 42)	73 (20.98)	14 (23.33)	59 (20.49)	
Initial SBP				0.503
<120 mmHg	5 (1.44)	1 (1.67)	4 (1.39)	
120 to 139 mmHg	20 (5.75)	1 (1.67)	19 (6.6)	
140 to 159 mmHg	113 (32.47)	20 (33.33)	93 (32.29)	
≥160 mmHg	210 (60.34)	38 (63.33)	172 (59.72)	
≥25% decline in eGFR				<0.001
None	277 (79.6)	0	276 (95.83)	
Stage 1	45 (12.93)	37 (61.67)	9 (3.13)	
Stage 2	16 (4.6)	13 (21.67)	3 (1.04)	
Stage 3	10 (2.87)	10 (16.67)	0	
<i>Mannitol dosage</i>				
Cumulative dose				0.010
<0.40g/kg	165 (47.41)	10 (31.67)	146 (50.69)	
>0.40g/kg	183 (52.59)	41 (68.33)	142 (49.31)	

Duration				0.095
<48 hours	83 (23.85)	9 (15)	74 (25.69)	
>48 hours	265 (76.15)	51 (85)	214 (74.31)	

143 eGFR, estimated glomerular filtration rate; NIHSS, National Institutes of Health Stroke Scale;

144 SBP, systolic blood pressure; SD, standard deviation

145 Patients who developed MI-AKI were mostly male (75%) and were 40 to 59 years old
 146 (65%). Most patients with MI-AKI (96.67%) were diagnosed with acute hemorrhagic stroke, and
 147 of these, a majority (83.33%) were intraparenchymal (P=0.042). About 63% of patients who
 148 developed MI-AKI had an initial systolic blood pressure of ≥ 160 mmHg while 50% had moderate
 149 to severe NIHSS scores (P= <0.001). During mannitol treatment, 61.67% developed stage 1 AKI
 150 (P ≤ 0.001). About 68% with AKI had a cumulative dose of mannitol >0.40 g/kg (P=0.010) and 51
 151 (85%) patients received mannitol for >48 hours (P=0.095).

152

153 **Table 2A. Co-morbidities**

	Mannitol-Induced Acute Kidney Injury			P-value
	Total	With	Without	
	(n=348)	(n=60, 17%)	(n=288, 83%)	
Frequency (%); Mean \pm SD				
<i>Comorbidities</i>				
Hypertension				0.446
None	149 (42.82)	28 (46.67)	121 (42.01)	
Stage I	9 (2.59)	0	9 (3.13)	
Stage II	190 (54.6)	32 (53.33)	158 (54.86)	

Diabetes mellitus				0.310
None	322 (92.53)	53 (88.33)	269 (93.4)	
Type I	1 (0.29)	0	1 (0.35)	
Type II	25 (7.18)	7 (11.67)	18 (6.25)	
Chronic kidney disease				<0.001
None	3 (0.86)	0	3 (1.04)	
Stage 1/G1	214 (61.49)	18 (30)	196 (68.06)	
Stage 2/G2	80 (22.99)	13 (21.67)	67 (23.26)	
Stage 3/G3a	25 (7.18)	10 (16.67)	15 (5.21)	
Stage 4/G3b	22 (6.32)	17 (28.33)	5 (1.74)	
Stage 4/G4	3 (0.86)	2 (3.33)	(0.35)	
Stage 5/G5	1 (0.29)	0	1 (0.35)	
Cardiovascular disease	2 (0.57)	2 (3.33)	0	0.029
Malignancy	0	0	0	-

154 SD, standard deviation

155 **Table 2B. Medications**

	Mannitol-Induced Acute Kidney Injury			P-value
	Total	With	Without	
	(n=348)	(n=60, 17%)	(n=288, 83%)	
Frequency (%); Mean ± SD				
Medication				

Anti-hypertensive	3 (0.86)	1 (1.67)	2 (0.69)	0.434
Diuretics	2 (0.57)	1 (1.67)	1 (0.35)	0.316
Nephrotoxic agents	0	0	0	-

156 SD, standard deviation

157 Univariate analysis showed that cardiovascular disease (P=0.029) and chronic kidney
 158 disease (CKD, P<0.001) were significantly associated with MI-AKI (Table 2A). A subgroup
 159 analysis of patients with CKD revealed that stages 3a to 4 had an increased incidence of AKI
 160 compared with stages 1 and 2, while stage 5 had no significant association most likely due to the
 161 early discontinuation of mannitol upon disease recognition (Table 2A). Among the medications
 162 evaluated, anti-hypertensives and diuretics did not demonstrate a significant association with MI-
 163 AKI (Table 2B).

164 Regarding final patient outcomes, about 62% of patients who had AKI died while 38.33%
 165 recovered from acute stroke (P<0.001). Spontaneous recovery with a return to baseline eGFR was
 166 observed in 41.67% of patients (P<0.001). On the other hand, worsening of renal function without
 167 RRT was observed in 45% of patients (P≤0.001) while 6.67% of patients underwent RRT
 168 (P=0.001) (Table 3).

169

170 **Table 3. The outcome of patients with MI-AKI**

	Mannitol-Induced Acute Kidney Injury			P-value
	Total	With	Without	
	(n=348)	(n=60, 17%)	(n=288, 83%)	
	Frequency (%)			
Mortality				<0.001

Alive	232 (66.67)	23 (38.33)	209 (72.57)	
Expired	116 (33.33)	37 (61.67)	79 (27.43)	
AKI	67 (19.25)	59 (98.33)	8 (2.78)	<0.001
Resolution of AKI	32 (9.20)	25 (41.67)	7 (2.43)	<0.001
Worsening of renal function without RRT	32 (9.20)	27 (45.00)	5 (1.74)	<0.001
Worsening of renal function with RRT	4 (1.15)	4 (6.67)	0	0.001

171 AKI, acute kidney injury; RRT, renal replacement therapy

172 Initial high NIHHS score of moderate to severe was seen to be associated with a higher
 173 risk of developing MI-AKI fivefold compared with a moderate NIHHS score (95% CI, 2.3–9.8;
 174 $P \leq 0.001$) (Table 4). For every CKD stage increase, the odds of having MI-AKI increase by about
 175 threefold (95% CI, 2.05–3.6; $P \leq 0.001$). Subarachnoid type of acute hemorrhagic stroke was 2.5
 176 times more likely to develop MI-AKI as compared with the intraparenchymal type of hemorrhagic
 177 stroke (95% CI, 1.12–5.72; $P = 0.024$). Lastly, a mannitol dose >0.40 g/kg cumulative dose for more
 178 than 48 hours increased the risk of having MI-AKI by twofold as compared with patients with a
 179 cumulative dose of <0.40 g/kg (95% CI, 1.22–4.00; $P = 0.008$).

180

181 **Table 4. Factors associated with MI-AKI**

Parameters	Crude odds ratio	95% CI	P-value
NIHHS score			
Minor (1 to 4)	2.8269	0.7066 to 11.309	0.142
Moderate (5 to 15)	(reference)	-	-

Moderate to severe (16 to 20)	4.8462	2.3818 to 9.8602	<0.001
Severe (21 to 42)	2.6832	1.1899 to 6.0503	0.017
Chronic kidney disease	2.7406	2.0596 to 3.6468	<0.001
Type of hemorrhagic stroke			
Subarachnoid	2.5429	1.1297 to 5.7238	0.024
Intraparenchymal	(reference)	-	-
Cumulative dose for 48 hours			
< 0.40g/kg	(reference)	-	-
> 0.40g/kg	2.2187	1.2287 to 4.0063	0.008

182

183 **Discussion**

184 This pilot study of patients admitted for stroke in EAMC outlined the risk factors and
185 outcomes in those who developed MI-AKI. The results showed the following important findings
186 in our patient subjects: firstly, our 17% incidence of MI-AKI appears to be higher compared with
187 the previous studies conducted by Kim et al (10.5%) and Lin et al (6.5%). Secondly, our study
188 supports the current observation that moderate to severe initial NIHSS scores, CKD stage 3a and
189 above, cardiovascular diseases such as heart failure, and high doses of mannitol infusion for
190 prolonged periods are likely independent risk factors for MI-AKI.

191 Previous studies have described a higher incidence of hemorrhagic stroke among patients
192 who develop MI-AKI (6, 7), while others suggest a link between ischemic stroke and MA-AKI
193 (8). However, the association between the type of stroke, either hemorrhagic or ischemic stroke,
194 there appears to be no association between the type of stroke and the risk of developing MI-AKI

195 (3) as reflected in this study. This indicates that MI-AKI is not an uncommon complication in
196 patients treated for stroke regardless of type.

197 Only patients treated with mannitol were included in the study, and to facilitate ruling out
198 other causes of AKI in this study, we excluded patients being treated with antibiotics for
199 nosocomial infections, including pneumonia, and pulmonary tuberculosis, as well as patients on
200 renal replacement therapy.

201 A high baseline NIHSS score has been shown in previous studies to increase the risk for
202 MI-AKI (3). Indeed, in our patients with moderate to severe NIHSS scores recruited in this study,
203 there is an apparent fivefold increase in the risk for MI-AKI. Although the NIHSS is established
204 especially as an instrument to evaluate the severity and prognosis of stroke, the strong association
205 between high NIHSS scores and AKI appears to be a result of the presence of severe illness and
206 concomitant complications (9); hence, our study shares consistent findings reported in the
207 literature. Unfortunately, among the study subjects with severe NIHSS scores, it was a challenge
208 to monitor kidney function throughout patient confinement due to their early demise from severe
209 stroke events. Also, most of the patients who received high-dose mannitol infusion developed MI-
210 AKI regardless of the presence of co-morbidities and high NIHSS scores.

211 Lin et al and Nomani et al found that with every increase in the stage of CKD, the odds of
212 having MI-AKI increase by 2.7 times compared to patients with normal renal function (3, 5) – a
213 finding that is likewise observed in our population. In the setting of renal impairment, the half-life
214 of mannitol has been seen to extend from 70 to 100 minutes to up to >36 hours causing mannitol
215 to accumulate in the kidneys (3). Mannitol is known to trigger water and reabsorption of salt along
216 the entire renal tubule resulting in electrolyte imbalance and volume depletion further increasing

217 the risk for renal injury in advanced CKD (3). Therefore, our results reflect comparable risk rates
218 with other studies owing to these recognized pathophysiologic mechanisms.

219 Unlike in previous studies, however, comorbidities including diabetes, hypertension, and
220 the use of anti-hypertensive medications and diuretics were not demonstrated to increase the risk
221 of MI-AKI (3, 5). The use of diuretics (i.e., mannitol) and contrast media in cardiovascular
222 diseases, such as heart failure and acute coronary events, increase the risk for AKI. Contrast-
223 induced AKI is a common complication post percutaneous coronary intervention as a result of
224 contrast nephrotoxicity (10). Mannitol generally brings about excessive intravascular volume
225 expansion, especially when administered in high doses and at rapid rates. In addition, volume
226 depletion may lead to renal vasoconstriction and ultimately acute renal injury (11). Hence, patients
227 being treated for cardiovascular diseases appear to be predictably at risk for MI-AKI as
228 demonstrated in our study. However, because of the small population where we identified only
229 two patients with cardiovascular disease, we are unable to draw a conclusive association. We
230 propose further analyses conducted in larger populations to provide a definitive association
231 between these comorbidities and MI-AKI (9).

232 The usual dose of mannitol for reduction of intracranial pressure is 0.12 to 0.20 g/kg/day
233 administered intravenously as a 20% solution over 30 to 60 minutes (5). The development of MI-
234 AKI was found to be dose-dependent and may occur in high-dose mannitol infusion (>0.20
235 g/kg/day or >0.40 g/kg in 48 hours) (5). Thus, monitoring the cumulative dose of mannitol appears
236 to have a notable clinical utility in stroke patients on mannitol. When the mannitol is discontinued
237 upon recognition of AKI, MI-AKI after stroke may be transient. However, some patients may have
238 worsening AKI requiring dialysis. In this study, 41.6% had spontaneous resolution of acute kidney
239 injury, and less than half had worsening renal function without RRT. Only 6.67 % of patients with

240 worsening renal function underwent renal RRT. In patients who develop MI-AKI, discontinuing
241 mannitol and starting dialysis, if necessary, are the clear management options (3).

242 Lastly, it was found that the mortality rate of patients who developed MI-AKI was high at
243 61.67%. However, the cause of death and its relation to mannitol-induced AKI were not clearly
244 defined in our subjects. We attribute this high mortality rate to brain herniation syndrome, multiple
245 organ dysfunction, and cardiac complications.

246 We acknowledge that we mainly identified the risk factors and established the clinical
247 outcomes of MI-AKI among a limited number of patients. The study excluded patients with other
248 medical conditions who developed AKI due to other causes. Further studies may employ serial
249 monitoring of renal function, mandatory diagnostic workup, such as serum osmolality by
250 spectrometry to calculate the osmolar gap and adequate monitoring of water balance such as fluid
251 input and urine output.

252 **Conclusion and recommendations**

253 This study showed that MI-AKI is associated with patient-specific factors which include a
254 high initial NIHSS score, chronic kidney disease, and a high dose of mannitol. Cardiovascular
255 disease also appears as a significant risk factor; however, MI-AKI in heart disease is likely due to
256 treatment-associated nephrotoxicity.

257 Early referral to a renal specialist is recommended for comorbidities including chronic
258 kidney disease stage 3 and above. Serial monitoring of patient renal function should be performed
259 especially for those with initial moderate to severe NIHSS scores and high-dose mannitol infusion.
260 In addition, it is recommended that a multi-center study be done to create a risk stratification tool
261 for the early identification of at-risk patients for MI-AKI.

262 **Ethical Considerations**


263 The study complied with the Data Privacy Act of 2012 and the National Guidelines for
264 Health and Health-Related Research (2007). The Institution and Ethics Review Board of EAMC
265 reviewed and approved the protocol and all relevant documents before data collection. A letter of
266 authorization was obtained from the Section Head of the Neurology Department prior to access to
267 the medical records. The data were collected and extracted from the patient's charts from the
268 medical records department; hence, informed consent was not necessary. General data,
269 laboratories, and medications were summarized from the chart and recorded. All the patients'
270 records were kept and stored in the Medical Records of EAMC in strict confidentiality for at least
271 6 months. A personal password-protected laptop was used for data collection. The chart
272 information was accessed by the researcher alone and no information was released to a third party.
273 The study did not receive financial grants from agencies, hence, there is no conflict of interest.

274 **References**

- 275 1. Collantes MV, Zuniga YH, Granada CN, Uezono DR, De Castillo LC, Enriquez CG, et al.
276 Current State of Stroke Care in the Philippines. *Front Neurol.* 2021;12:665086.
- 277 2. Navarro JC, Venketasubramanian N. Stroke Burden and Services in the Philippines.
278 *Cerebrovascular Diseases Extra.* 2021;11(2):52-4.
- 279 3. Lin SY, Tang SC, Tsai LK, Yeh SJ, Shen LJ, Wu FL, et al. Incidence and Risk Factors for
280 Acute Kidney Injury Following Mannitol Infusion in Patients With Acute Stroke: A Retrospective
281 Cohort Study. *Medicine (Baltimore).* 2015;94(47):e2032.
- 282 4. Dunn IF, Kim AH, Gormley WB. Brain Trauma. In: Squire LR, editor. *Encyclopedia of*
283 *Neuroscience.* Oxford: Academic Press; 2009. p. 407-16.

- 284 5. Nomani AZ, Nabi Z, Rashid H, Janjua J, Nomani H, Majeed A, et al. Osmotic nephrosis
285 with mannitol: review article. *Ren Fail.* 2014;36(7):1169-76.
- 286 6. Kim MY, Park JH, Kang NR, Jang HR, Lee JE, Huh W, et al. Increased risk of acute kidney
287 injury associated with higher infusion rate of mannitol in patients with intracranial hemorrhage. *J*
288 *Neurosurg.* 2014;120(6):1340-8.
- 289 7. Dziedzic T, Szczudlik A, Klimkowicz A, Rog TM, Slowik A. Is mannitol safe for patients
290 with intracerebral hemorrhages? Renal considerations. *Clin Neurol Neurosurg.* 2003;105(2):87-9.
- 291 8. Nadkarni GN, Patel AA, Konstantinidis I, Mahajan A, Agarwal SK, Kamat S, et al.
292 Dialysis Requiring Acute Kidney Injury in Acute Cerebrovascular Accident Hospitalizations.
293 *Stroke.* 2015;46(11):3226-31.
- 294 9. Huang Y, Wan C, Wu G. Acute kidney injury after a stroke: A PRISMA-compliant meta-
295 analysis. *Brain Behav.* 2020;10(9):e01722.
- 296 10. Kim S, Sung J, Kang WC, Ahn SY, Kim DK, Chin HJ, et al. Increased plasma osmolar
297 gap is predictive of contrast-induced acute kidney injury. *Tohoku J Exp Med.* 2012;228(2):109-
298 17.
- 299 11. Dai H, Ding F, Ma J, Zhao S. Risk factors for acute kidney injury after intracranial
300 hemorrhage. *Neuro Endocrinol Lett.* 2022;43(5):257-64.

301



Figure